446 related articles for article (PubMed ID: 12800187)
21. Retinoic acid modulates stem cell factor secretion by human neuroblastoma cell lines.
Strippoli P; Bagnara GP; Montanaro L; Timeus F; Ferreri AM; Rocchi P
Anticancer Res; 2000; 20(6B):4361-6. PubMed ID: 11205272
[TBL] [Abstract][Full Text] [Related]
22. Retinoic acid enhances sensitivity of neuroblastoma cells for imatinib mesylate.
Neumann I; Foell JL; Bremer M; Volkmer I; Korholz D; Burdach S; Staege MS
Pediatr Blood Cancer; 2010 Sep; 55(3):464-70. PubMed ID: 20658618
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.
Heinrich MC; Griffith DJ; Druker BJ; Wait CL; Ott KA; Zigler AJ
Blood; 2000 Aug; 96(3):925-32. PubMed ID: 10910906
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
25. c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells.
Ricotti E; Fagioli F; Garelli E; Linari C; Crescenzio N; Horenstein AL; Pistamiglio P; Vai S; Berger M; di Montezemolo LC; Madon E; Basso G
Blood; 1998 Apr; 91(7):2397-405. PubMed ID: 9516139
[TBL] [Abstract][Full Text] [Related]
26. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
Frost MJ; Ferrao PT; Hughes TP; Ashman LK
Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
[TBL] [Abstract][Full Text] [Related]
27. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Clin Cancer Res; 2001 Dec; 7(12):3884-93. PubMed ID: 11751479
[TBL] [Abstract][Full Text] [Related]
28. Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis.
Lefevre G; Glotin AL; Calipel A; Mouriaux F; Tran T; Kherrouche Z; Maurage CA; Auclair C; Mascarelli F
J Biol Chem; 2004 Jul; 279(30):31769-79. PubMed ID: 15145934
[TBL] [Abstract][Full Text] [Related]
29. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells.
Litz J; Krystal GW
Mol Cancer Ther; 2006 Jun; 5(6):1415-22. PubMed ID: 16818499
[TBL] [Abstract][Full Text] [Related]
30. STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Wang-Rodriguez J; Lopez JP; Altuna X; Chu TS; Weisman RA; Ongkeko WM
Laryngoscope; 2006 Aug; 116(8):1409-16. PubMed ID: 16885745
[TBL] [Abstract][Full Text] [Related]
31. KIT overexpression induces proliferation in astrocytes in an imatinib-responsive manner and associates with proliferation index in gliomas.
Blom T; Fox H; Angers-Loustau A; Peltonen K; Kerosuo L; Wartiovaara K; Linja M; Jänne OA; Kovanen P; Haapasalo H; Nupponen NN
Int J Cancer; 2008 Aug; 123(4):793-800. PubMed ID: 18506689
[TBL] [Abstract][Full Text] [Related]
32. Stem cell factor is not essential for cell survival and proliferation of soft tissue sarcoma of neuroectodermal origin.
Ricotti E; Bertorello N; Vai S; Pagani A; Cordero Di Montezemolo L; Madon E; Basso G
Haematologica; 1999 Oct; 84(10):879-86. PubMed ID: 10509034
[TBL] [Abstract][Full Text] [Related]
33. Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27(KIP1) as a consequence of c-Abl inhibition.
Lupino E; Ramondetti C; Buccinnà B; Piccinini M
Biochem Pharmacol; 2014 Nov; 92(2):235-50. PubMed ID: 25264277
[TBL] [Abstract][Full Text] [Related]
34. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis.
Rassidakis GZ; Georgakis GV; Oyarzo M; Younes A; Medeiros LJ
Mod Pathol; 2004 Aug; 17(8):946-53. PubMed ID: 15105813
[TBL] [Abstract][Full Text] [Related]
35. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
[TBL] [Abstract][Full Text] [Related]
36. Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec).
Samoszuk M; Corwin MA
Int J Cancer; 2003 Sep; 106(5):647-52. PubMed ID: 12866022
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
[TBL] [Abstract][Full Text] [Related]
38. Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
Maulik G; Bharti A; Khan E; Broderick RJ; Kijima T; Salgia R
J Environ Pathol Toxicol Oncol; 2004; 23(4):237-51. PubMed ID: 15511212
[TBL] [Abstract][Full Text] [Related]
39. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
Hotfilder M; Lanvers C; Jürgens H; Boos J; Vormoor J
Cancer Chemother Pharmacol; 2002 Aug; 50(2):167-9. PubMed ID: 12172985
[TBL] [Abstract][Full Text] [Related]
40. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
